neuroendocrine tumor (Cancer)
Information
- Disease name
- neuroendocrine tumor
- Disease ID
- DOID:169
- Description
- "An endocrine gland cancer that has_material_basis_in neuroendocrine cells." [url:http\://en.wikipedia.org/wiki/Neuroendocrine_cell, url:http\://en.wikipedia.org/wiki/Neuroendocrine_tumor, url:http\://www.cancer.gov/dictionary?CdrID=44904]
Disease area statistics
Chromosome band
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00569127 | Active, not recruiting | Phase 3 | Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor | December 1, 2007 | January 31, 2025 |
| NCT03012789 | Active, not recruiting | N/A | Surgical Intervention and the NETest | May 15, 2017 | June 2026 |
| NCT04400474 | Active, not recruiting | Phase 2 | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study | October 7, 2020 | March 2024 |
| NCT00434109 | Completed | Phase 2 | Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization | November 2006 | February 2012 |
| NCT00789841 | Completed | Gastrointestinal Motility in Patients With Neuroendocrine Tumors | September 2008 | May 2010 | |
| NCT00804336 | Completed | Phase 1 | Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | October 2008 | April 2015 |
| NCT00942682 | Completed | Phase 1 | Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | July 2009 | March 2013 |
| NCT01024387 | Completed | Phase 2 | AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | March 2010 | January 2017 |
| NCT00131911 | Completed | Phase 2 | Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | June 2005 | April 2013 |
| NCT00165230 | Completed | Phase 2 | Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors | May 2002 | July 2006 |
| NCT00363051 | Completed | Phase 2 | Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy | June 2006 | April 2012 |
| NCT01099540 | Completed | Phase 2 | Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor | April 2010 | March 2013 |
| NCT01476592 | Completed | N/A | A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors | December 2011 | October 11, 2018 |
| NCT01849523 | Completed | N/A | Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study | October 2013 | August 2014 |
| NCT01869725 | Completed | Phase 2 | Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT | April 1, 2013 | December 26, 2018 |
| NCT02147106 | Completed | Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study | May 2014 | March 2017 | |
| NCT02472678 | Completed | N/A | Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor | May 2015 | May 2017 |
| NCT02481804 | Completed | N/A | Optimal Feeding for NET Patients | May 2015 | March 2016 |
| NCT03143946 | Completed | N/A | DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor | December 15, 2016 | August 2019 |
| NCT03197012 | Completed | Early Phase 1 | Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor | July 1, 2017 | May 31, 2019 |
| NCT03411915 | Completed | Phase 1 | A Study of XmAb®18087 in Subjects With NET and GIST | January 22, 2018 | October 26, 2021 |
| NCT05816720 | Completed | Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®) | September 1, 2021 | January 31, 2022 | |
| NCT02270567 | Enrolling by invitation | RegisterNET - A Registry for Neuroendocrine Tumors in the USA | February 2015 | December 2025 | |
| NCT04837885 | Recruiting | Phase 2 | Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases | September 24, 2021 | September 24, 2024 |
| NCT02628067 | Recruiting | Phase 2 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | December 18, 2015 | May 4, 2027 |
| NCT05069220 | Recruiting | Early Phase 1 | 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor | September 1, 2021 | December 2026 |
| NCT04907643 | Recruiting | N/A | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | October 5, 2021 | March 2026 |
| NCT05749289 | Recruiting | Phase 2/Phase 3 | Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor | December 20, 2022 | December 20, 2025 |
| NCT00227617 | Terminated | Phase 2/Phase 3 | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | June 8, 2005 | February 2016 |
| NCT04073017 | Terminated | N/A | Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency | November 4, 2019 | May 18, 2021 |
| NCT02177773 | Terminated | Phase 1/Phase 2 | GA-68 DOTA-TOC of Somatostatin Positive Malignancies | June 23, 2014 | August 7, 2017 |
| NCT01448083 | Unknown status | Heart/Mediastinal Ratio Study for Potential Equivalence of Heart/Mediastinal Ratios at One and Two Hours to the Traditional Heart/Mediastinal Ratio Obtained at Four Hours | October 2011 | ||
| NCT02092714 | Unknown status | Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors | October 16, 2013 | November 16, 2020 | |
| NCT02038738 | Unknown status | Phase 1/Phase 2 | 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors | March 2014 | |
| NCT00569738 | Unknown status | Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors | December 2008 | December 2010 | |
| NCT03466216 | Unknown status | Phase 1 | Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET | February 5, 2018 | July 1, 2022 |
| NCT01048086 | Withdrawn | Phase 2 | 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) | June 2009 | November 2013 |
- Disase is a (Disease Ontology)
- DOID:170
- Cross Reference ID (Disease Ontology)
- ICD10CM:D3A.8
- Cross Reference ID (Disease Ontology)
- ICD9CM:209-209.99
- Cross Reference ID (Disease Ontology)
- ICDO:8240/3
- Cross Reference ID (Disease Ontology)
- MESH:D018358
- Cross Reference ID (Disease Ontology)
- NCI:C3809
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:55937004
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0206754
- Exact Synonym (Disease Ontology)
- neuroendocrine neoplasm